Mirtazapine for Long-Term Insomnia: Limited Evidence and Not First-Line
Mirtazapine is not recommended as a first-line treatment for chronic insomnia, and while recent evidence suggests short-term efficacy, its long-term effectiveness remains poorly established with concerning tolerability issues that limit sustained use.
Treatment Hierarchy for Chronic Insomnia
The established treatment algorithm for chronic insomnia is clear 1:
First-line: Cognitive behavioral therapy for insomnia (CBT-I) - this is a standard recommendation
Second-line pharmacotherapy (if CBT-I fails):
- Short-intermediate acting benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon, temazepam) or ramelteon
- Alternative BzRA or ramelteon if initial agent unsuccessful
Third-line: Sedating antidepressants including mirtazapine, trazodone, amitriptyline, doxepin - especially when comorbid depression/anxiety is present 1
Critical Evidence Gaps for Mirtazapine
The FDA label explicitly states that mirtazapine is not FDA-approved for insomnia and its efficacy for this indication is not well established 1, 2. The drug is only indicated for major depressive disorder 2.
The 2016 American College of Physicians guideline found insufficient evidence to determine the effectiveness of trazodone (and by extension, other sedating antidepressants like mirtazapine) for chronic insomnia 3. The 2017 AASM guideline similarly noted the "relative paucity of data concerning long-term usage" and "weak level of evidence supporting their efficacy" 4.
Recent Research Findings
Short-Term Efficacy (Strongest Recent Evidence)
The 2025 MIRAGE trial 5 - the most recent and highest quality placebo-controlled study - demonstrated that in older adults (≥65 years) with chronic insomnia:
- Mirtazapine 7.5 mg for 28 days significantly reduced Insomnia Severity Index scores compared to placebo (mean difference -6.5 vs -2.9, p=0.003)
- Improved wake after sleep onset, total sleep time, and sleep efficiency
- However, 6 participants discontinued due to adverse events vs only 1 in placebo group
The 2025 DREAMING trial 6 in general practice patients (18-85 years) found:
- Mirtazapine 7.5-15 mg showed statistically significant and clinically relevant reduction at 6 weeks
- But no significant differences from 12 weeks onward
- This suggests tolerance development or waning efficacy with continued use
Long-Term Use Concerns
A 2015 retrospective study 7 suggested sustained efficacy over 3+ months at very low doses (7.5 mg), with 86.95% response rate. However, this was retrospective, uncontrolled, and lower quality evidence compared to the recent RCTs.
The critical finding: The most rigorous recent evidence shows efficacy diminishes after 6-12 weeks 6, directly contradicting the premise of long-term effectiveness.
Safety and Tolerability Issues
The FDA label warns of multiple concerning adverse effects 2:
- Somnolence (54% vs 18% placebo) - leading to 10.4% discontinuation
- Weight gain (7.5% gained ≥7% body weight vs 0% placebo)
- QTc prolongation with risk of Torsades de Pointes
- Increased appetite (17% vs 2% placebo)
- Risk of DRESS syndrome, hyponatremia, seizures
These side effects are particularly problematic for long-term use and may outweigh benefits in primary insomnia without depression.
Clinical Algorithm for Decision-Making
When to consider mirtazapine for insomnia:
Primary insomnia has failed:
- CBT-I trial completed
- BzRA or ramelteon trial unsuccessful or contraindicated
Comorbid conditions present:
- Major depressive disorder (use full antidepressant dose, not low-dose for insomnia)
- Anxiety disorder
- Poor appetite/weight loss
Patient factors favoring mirtazapine:
- Cannot tolerate BzRAs
- History of substance abuse (mirtazapine non-scheduled)
- Need for appetite stimulation
When NOT to use mirtazapine:
- As first-line therapy
- Primary insomnia without comorbidities
- Patients concerned about weight gain
- Patients with cardiovascular disease (QTc concerns)
- Expectation of long-term nightly use beyond 3 months
Practical Prescribing Approach
If mirtazapine is chosen:
- Start 7.5 mg at bedtime (lowest effective dose per evidence 7, 5)
- Reassess at 6 weeks for efficacy
- Plan for discontinuation or intermittent use after 12 weeks given evidence of waning efficacy 6
- Monitor weight, appetite, daytime sedation
- Combine with CBT-I whenever possible 1
- Use lowest effective maintenance dose 1
The evidence strongly suggests mirtazapine should not be viewed as a long-term solution for primary insomnia - its role is limited to short-term use (weeks to 3 months) or as adjunctive treatment when comorbid depression/anxiety justifies antidepressant therapy at therapeutic doses.